Obstructive Lung Disease — COPD and Emphysema

Inhalational oxidant burden (the dominant mechanism)

• Cigarette smoking: the cause of the large majority of US cases. Smoke recruits neutrophils and macrophages, inactivates alpha-1 antitrypsin by oxidizing its active-site methionine, and tips the protease–antiprotease balance toward elastolysis. Risk rises with pack-years, but only a minority of smokers develop clinically significant airflow obstruction — susceptibility is partly genetic.
• Biomass fuel and indoor smoke: wood/dung/coal cooking fires in poorly ventilated homes; the classic stem is a never-smoking woman from a low-resource setting. GOLD explicitly lists biomass exposure as a major global cause.
• Occupational dusts, vapors, and fumes: coal, silica, cadmium, grain dust, welding fumes, isocyanates. These act additively with tobacco.

Genetic and host factors (non-modifiable)

• Alpha-1 antitrypsin deficiency: PiZZ (and PiSZ) genotypes cause misfolded Z protein to polymerize and be retained in hepatocytes — hence low serum levels plus periportal PAS-positive, diastase-resistant globules and cirrhosis. Unopposed neutrophil elastase produces panacinar, lower-lobe (basilar) emphysema, in contrast to the upper-lobe centriacinar pattern of smoking. Suspect it in emphysema before age 45, basilar-predominant disease, minimal smoking history, or unexplained liver disease.
• Impaired lung growth: prematurity/bronchopulmonary dysplasia, low birth weight, severe childhood respiratory infections, and in-utero tobacco exposure lower peak attained FEV₁, so normal age-related decline crosses the disease threshold earlier.
• Airway hyperresponsiveness and chronic asthma: accelerate FEV₁ decline and predispose to fixed obstruction (asthma–COPD overlap).
• Other: advancing age, male sex historically (now converging), HIV, prior pulmonary tuberculosis with structural airway damage.

Modifiable versus non-modifiable — how examiners frame it

• Modifiable: tobacco (including secondhand smoke), biomass and occupational exposure, ambient air pollution, recurrent untreated respiratory infection, poor vaccination status. Smoking cessation is the only intervention that alters the rate of FEV₁ decline.
• Non-modifiable: alpha-1 antitrypsin genotype, age, impaired early-life lung growth.
• Screening caveat: USPSTF recommends against spirometric screening of asymptomatic adults, but does recommend annual low-dose CT lung cancer screening for adults 50–80 with a ≥20 pack-year history who currently smoke or quit within 15 years.

• Oxidative stress and inflammation: Cigarette smoke and noxious particles activate macrophages and neutrophils, releasing proteases (elastase, cathepsin G) and reactive oxygen species. This overwhelms antiprotease defenses (alpha-1 antitrypsin, tissue inhibitors of metalloproteinases), creating a protease-antiprotease imbalance that drives parenchymal destruction.

• Emphysematous destruction: Loss of elastic recoil and alveolar surface area occurs through progressive alveolar wall destruction. In centriacinar emphysema (smoking-related), proximal alveoli are preferentially damaged while distal alveoli are spared; in panacinar emphysema (alpha-1 antitrypsin deficiency), all alveoli are uniformly destroyed, typically affecting lower lobes.

• Small airway disease: Chronic inflammation causes goblet cell metaplasia, smooth muscle hypertrophy, and mucus plugging in terminal and respiratory bronchioles. Loss of elastic support from surrounding parenchyma leads to dynamic airway collapse during expiration, causing air trapping and intrinsic positive end-expiratory pressure (auto-PEEP).

• Mucus hypersecretion: Chronic irritation promotes goblet cell proliferation in the airway epithelium, producing excessive mucus. This contributes to the chronic productive cough phenotype and airway obstruction, particularly in chronic bronchitis.

• Pulmonary hypertension development: Hypoxic pulmonary vasoconstriction, loss of capillary bed from emphysema, and inflammatory mediators lead to increased right ventricular afterload. Progressive cor pulmonale can develop in advanced disease.

• Systemic effects: COPD triggers systemic inflammation (elevated TNF-α, IL-6, fibrinogen), contributing to skeletal muscle wasting, osteoporosis, cardiovascular disease, and increased mortality independent of lung function.

• Chronic productive cough: Often the earliest symptom, present for ≥3 months. The "smoker's cough" is initially intermittent but becomes persistent. Cough may be worse in morning due to overnight mucus accumulation. This is the hallmark of chronic bronchitis phenotype.

• Dyspnea on exertion (DOE): Progressive exertional breathlessness is the cardinal symptom driving patients to seek care. Initially occurs with moderate exertion but worsens over years. May be accompanied by use of accessory muscles, pursed-lip breathing (patient-adopted compensatory mechanism), and prolonged expiration.

• Wheezing and chest tightness: Patients often report an audible wheeze or sensation of chest tightness, particularly with exertion or upper respiratory infections. This overlap with asthma can create diagnostic confusion.

• Acute exacerbations: Episodic worsening of dyspnea, cough, and sputum production triggered by respiratory infections, air pollution, or unknown causes. Exacerbations are hallmark events defining disease course and prognosis; frequent exacerbations (≥2/year) indicate more severe disease.

• Barrel chest and pursed-lip breathing: Chronic air trapping leads to increased anteroposterior chest diameter. Patients spontaneously adopt pursed-lip breathing to maintain positive airway pressure during expiration, reducing dynamic collapse and improving ventilation efficiency.

• Cor pulmonale signs: Advanced disease may present with peripheral edema, elevated jugular venous pressure, and hepatomegaly from right heart failure. Severe hypoxemia leads to cyanosis ("blue bloater" phenotype).

• Cachexia and systemic manifestations: Weight loss, skeletal muscle wasting, weakness, and fatigue reflect systemic inflammation. Osteoporosis from steroid use and disease effects increases fracture risk. Depression and anxiety are common comorbidities.

• Clinical phenotypes: "Pink puffer" (emphysema-predominant: thin, pursed-lip breathing, maintenance of oxygenation) vs. "blue bloater" (chronic bronchitis-predominant: obese, hypoxemic, cor pulmonale); most patients have mixed features.

• Spirometry (gold standard): Post-bronchodilator FEV₁/FVC <0.70 confirms airflow obstruction. FEV₁ percent predicted stages severity: Stage 1 (≥80%), Stage 2 (50-79%), Stage 3 (30-49%), Stage 4 (<30%). Improvement of <12% and <200 mL after bronchodilator argues against asthma. FEV₁/FVC is reduced due to early airway closure; FVC may be normal or reduced (air trapping).

• Chest X-ray: May be normal in mild disease. In emphysema, findings include hyperinflation (flattened diaphragms, increased retrosternal air space), bullae (large lucencies), and reduced vascular markings. Chronic bronchitis shows bronchial wall thickening ("tram-track" sign) and increased bronchus-to-vessel ratio. CXR helps exclude alternative diagnoses (pneumonia, pneumothorax, malignancy).

• High-resolution CT (HRCT): Sensitive for detecting emphysema distribution and severity; useful when diagnosis is unclear or in younger patients without significant smoking history (consider alpha-1 antitrypsin deficiency). Helps stratify emphysema phenotype and assess for bronchiectasis.

• Lung volumes (plethysmography): Elevated total lung capacity (TLC) and functional residual capacity (FRC) reflect air trapping. Reduced DLCO (diffusing capacity) is typical in emphysema due to alveolar destruction; less reduced in pure chronic bronchitis or with concurrent interstitial disease.

• Alpha-1 antitrypsin level: Screen all COPD patients, especially those <45 years old, with basilar-predominant emphysema, or without significant smoking history. PiZZ (severe deficiency) and PiSZ (intermediate deficiency) genotypes confer high risk. Level <57 µmol/L (11 mg/dL) requires further investigation and may warrant augmentation therapy.

• Arterial blood gas (ABG): Assess in moderate-severe disease or exacerbation. Hypoxemia (PaO₂ <55-60 mmHg on room air) indicates need for supplemental oxygen. Hypercapnia (PaCO₂ >45 mmHg) suggests severe airflow obstruction with ventilatory failure; chronic hypercapnia with elevated bicarbonate represents respiratory acidosis with metabolic compensation.

• Important diagnostic exclusions: Asthma (reversibility of obstruction, often younger onset, atopy), interstitial lung disease (restrictive pattern with reduced FVC, crackles), and congestive heart failure (elevated BNP, cardiomegaly, pulmonary edema pattern).

• Smoking cessation (foundational): The single most effective intervention. Varenicline (1-2 mg daily) or bupropion (300 mg daily) combined with nicotine replacement therapy significantly improves quit rates. Even brief physician counseling improves outcomes. Every patient visit offers opportunity to reinforce cessation.

• Inhaled short-acting beta-2 agonists (SABA): Albuterol 2

Disease-related — emergencies first

• Acute exacerbation (AECOPD): increased dyspnea, sputum volume, and sputum purulence, usually triggered by viral infection (rhinovirus) or bacteria (H. influenzae, M. catarrhalis, S. pneumoniae). Mechanism is worsened airway inflammation and mucus plugging with dynamic hyperinflation. GOLD supports short-course systemic corticosteroids and antibiotics when purulence plus increased sputum or dyspnea are present.
• Acute hypercapnic respiratory failure — EMERGENCY: rising PaCO₂ with acute respiratory acidosis (pH <7.35), somnolence, asterixis. Auto-PEEP raises the inspiratory threshold load until respiratory muscles fatigue. Noninvasive positive-pressure ventilation (BiPAP) is first-line per GOLD and reduces intubation and mortality; intubate for depressed sensorium, hemodynamic instability, or NIV failure.
• Oxygen-induced hypercapnia: uncontrolled high-FiO₂ therapy worsens CO₂ retention via release of hypoxic pulmonary vasoconstriction (V/Q mismatch), the Haldane effect, and some loss of hypoxic drive. Titrate to SpO₂ 88–92%.
• Secondary spontaneous pneumothorax — EMERGENCY: rupture of a subpleural bulla; sudden pleuritic pain and unilateral absent breath sounds. Poorly tolerated because of limited reserve; tension physiology (hypotension, tracheal deviation) demands immediate needle decompression.
• Pulmonary hypertension and cor pulmonale: chronic hypoxic vasoconstriction plus capillary bed destruction → RV failure with JVD, hepatomegaly, edema, loud P₂. Long-term oxygen therapy for resting hypoxemia (PaO₂ ≤55 mm Hg or SpO₂ ≤88%) is one of the few mortality-reducing interventions.
• Secondary polycythemia from chronic hypoxemia, lung cancer (shared smoking exposure, risk independent of pack-years), pneumonia, venous thromboembolism, cachexia/sarcopenia, osteoporosis, and depression.

Treatment-related

• Inhaled corticosteroids: oropharyngeal candidiasis, dysphonia, and increased pneumonia risk — the reason GOLD reserves ICS for exacerbation-prone patients, especially with blood eosinophilia.
• Systemic corticosteroids: hyperglycemia, osteoporosis, myopathy, adrenal suppression, neuropsychiatric effects.
• Beta-2 agonists: tremor, sinus tachycardia, hypokalemia. Antimuscarinics: dry mouth, urinary retention, acute angle-closure glaucoma from nebulized drug reaching the eyes.
• Theophylline: narrow therapeutic index — nausea, arrhythmia, seizure. Chronic azithromycin: QT prolongation, hearing loss, macrolide resistance. Roflumilast: diarrhea, weight loss, psychiatric symptoms.

• The diagnostic number: post-bronchodilator FEV₁/FVC <0.70 defines obstruction; FEV₁ % predicted then grades severity (GOLD 1–4). If a stem gives only pre-bronchodilator values, the single best next step is repeat spirometry after a bronchodilator — not imaging, not empiric therapy.
• Chronic bronchitis is a clinical diagnosis: productive cough ≥3 months per year for 2 consecutive years. The pathologic correlate is a Reid index >0.4 (mucous gland layer thickness relative to bronchial wall). Emphysema, by contrast, is defined anatomically.
• The one association examiners love: alpha-1 antitrypsin deficiency → panacinar, basilar emphysema in a young or never-smoking patient, plus liver disease with PAS-positive, diastase-resistant hepatocyte globules. Smoking-related centriacinar emphysema is upper-lobe. Do not reverse these.
• Only three things clearly reduce mortality: smoking cessation, long-term oxygen therapy in patients with resting hypoxemia (PaO₂ ≤55 mm Hg or SpO₂ ≤88%), and lung volume reduction surgery in selected upper-lobe-predominant emphysema with low exercise capacity (NETT). Bronchodilators improve symptoms and exacerbations, not survival.
• Oxygen distractor: the answer is never "100% non-rebreather" for a stable hypercapnic COPD patient. Target SpO₂ 88–92%; give BiPAP for acute hypercapnic acidosis.
• Pulmonary rehabilitation improves dyspnea, exercise capacity, and quality of life and is recommended by ATS/ERS after exacerbation and for symptomatic patients — a frequently overlooked "best next step" in a patient already on maximal inhalers.
• Vaccination is guideline-mandated care: annual influenza, pneumococcal, COVID-19, Tdap, and RSV vaccination per CDC/ACIP schedules for adults with chronic lung disease.
• Distinguishing distractor: significant bronchodilator reversibility, atopy, and diurnal variability point to asthma; a low DLCO with hyperinflation points to emphysema, while a normal or high DLCO with obstruction fits asthma or chronic bronchitis.